Sparsentan receives Orphan Drug Designation for primary IgA nephropathy in Japan ...Middle East

TOKYO, Dec. 2, 2024 /PRNewswire/ -- Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. ("Travere") and currently in phase III clinical trials in Japan, has received Orphan Drug Designation from the...

Read More Details
Finally We wish PressBee provided you with enough information of ( Sparsentan receives Orphan Drug Designation for primary IgA nephropathy in Japan )

Also on site :

• Lou Christie, “Lightnin’ Strikes” and “Rhapsody in the Rain” Singer, Dies at 82
• Bruce Springsteen Hints at New Music and Reveals Upcoming Box Set
• Royal Family Cousin Has Strong Opinions on Meghan Markle Claiming 'Sussex' Name